Forbes contributors publish independent expert analyses and insights. Mark Minevich is a NY-based strategist focused on human centric AI. The year ahead looks set to become one of tremendous change.

Upfront modified FOLFOXIRI plus panitumumab (pan) versus FOLFOX/pan for unresectable RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: Overall survival (OS) results from the ...

Short-course radiotherapy-based total neoadjuvant therapy combined with tislelizumab in the treatment of locally advanced rectal cancer (Neo-STAR): Early outcomes of a prospective, randomized phase II ...

PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...

Company plans to continue rapidly advancing clinical development program for VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in several advanced KRAS G12D ...

NEW YORK--(BUSINESS WIRE)--TJC LP (“TJC” or “the Firm”), a middle-market private equity firm investing primarily in North America, today announced that the Firm earned the #4 ranking on the HEC ...

As we do every year, we’ve gathered data around some of the most pivotal news stories of 2025, including President Donald Trump’s return to the White House, the changing U.S. immigration landscape and ...

This was one wild year for music — as the late, great Ozzy would say, it was a crazy train. In 2025, you never knew where your next favorite song was coming from. Some of the year’s best songs were ...

2025 was a year that posed a lot of questions for movie lovers: Did the success of Sinners prove that there was still a mass audience hungry for original (read: non-IP) stories on a blockbuster level?

Ultraviolet light reveals a human handprint on the shell of a green sea turtle—demonstrating a cutting-edge technique for capturing forensic evidence to be used against poachers and animal traffickers ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...